

Monument Health Clinical Research Trials

Last updated on: 9/11/2023

Heart Failure Trials	Trial Title	ClinicalTrials.gov Link
DAPA ACT HF	Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68	https://clinicaltrials.gov/ct2/show/NCT04363697?term=DAPA+ACT+HF&draw=2&rank=1
ALLAY-HF	Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.	https://clinicaltrials.gov/ct2/show/NCT05685303?term=NCT05685303&draw=2&rank=1
HERMES	A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation	https://clinicaltrials.gov/ct2/show/NCT05636176?term=NCT05636176&draw=2&rank=1
Device Trials	Trial Title	ClinicalTrials.gov Link
ELEGANCE	Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature	https://clinicaltrials.gov/ct2/show/NCT04674969?term=NCT04674969&draw=2&rank=1
EXPAND TAVR II	Evolut™ EXPAND TAVR II Pivotal Trial	https://clinicaltrials.gov/ct2/show/NCT05149755?term=expand+tavr+ii&draw=2&rank=1
General Cardiology	Trial Title	ClinicalTrials.gov Link
NODE-X		
SOS-AMI	Selatogrel Outcome Study in Suspected Acute Myocardial Infarction	https://clinicaltrials.gov/ct2/show/NCT04957719?term=NCT04957719&draw=2&rank=1
PREVAIL	Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients with Cardiovascular Disease	https://clinicaltrials.gov/ct2/show/NCT05202509?term=NCT05202509&draw=2&rank=1
VICTORION1 PREVENT	A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients	https://clinicaltrials.gov/study/NCT05739383?term=CKJX839D12302&rank=1
OCEANIC-AF	A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke	https://clinicaltrials.gov/ct2/show/NCT05643573?term=oceanic-af&draw=2&rank=1
OCEAN(a) Outcomes	Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction	https://clinicaltrials.gov/ct2/show/NCT05581303?term=NCT05581303&draw=2&rank=1
CORE-2	A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia	https://clinicaltrials.gov/ct2/show/NCT05681351?term=NCT05552326&draw=2&rank=2
ESSENCE	A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia	https://clinicaltrials.gov/ct2/show/NCT05610280?term=NCT05610280&draw=2&rank=1
LIBREXIA-ACS	A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome	https://clinicaltrials.gov/study/NCT05754957?term=librexia-acs&rank=1
LIBREXIA-AF	A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation	https://clinicaltrials.gov/study/NCT05757869?term=librexia-af&rank=1